Literature DB >> 6352489

Natural cell-mediated cytotoxicity against Candida albicans induced by cyclophosphamide: nature of the in vitro cytotoxic effector.

M Baccarini, F Bistoni, P Puccetti, E Garaci.   

Abstract

We have recently reported the in vivo modulation of resistance to experimental Candida albicans infection by cyclophosphamide (150 mg/kg intraperitoneally) in mice and have shown that increased resistance to the microbial challenge occurs 12 to 21 days after treatment with the drug (Bistoni et al., Infect. Immun. 40: 46-55, 1983). The event is accompanied by the appearance of a highly candidacidal cell population in the spleen and the activation of a subpopulation of natural cytotoxic effectors reactive in vitro against YAC-1 tumor cells. We now provide evidence that these anti-YAC-1 cytotoxic effectors are clearly distinct from the cyclophosphamide-induced candidacidal effectors, which seem to belong to a macrophage-monocyte lineage. The enhanced cytotoxic activity induced by cyclophosphamide was not restricted to C. albicans but was also exerted against a panel of Candida strains.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352489      PMCID: PMC264515          DOI: 10.1128/iai.42.1.1-9.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Natural cytotoxicity of mouse monocytes and macrophages.

Authors:  A Tagliabue; A Mantovani; M Kilgallen; R B Herberman; J L McCoy
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

Review 2.  Natural cell-mediated immunity.

Authors:  R B Herberman; H T Holden
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

3.  Direct comparison of three isotopic release microtoxicity assays as measures of cell-mediated immunity to Gross virus-induced lymphomas in rats.

Authors:  R K Oldham; J R Ortaldo; H T Holden; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1977-04       Impact factor: 13.506

4.  Natural cytotoxic cells against solid tumors in mice. I. Strain and age distribution and target cell susceptibility.

Authors:  O Stutman; C J Paige; E F Figarella
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

5.  Macrophage-lymphocyte interaction in migration inhibition factor (MIF) production against soluble or cellular tumor-associated antigens. I. Characteristics and genetic control of two different mechanisms of stimulating MIF production.

Authors:  S Landolfo; R B Herberman; H T Holden
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

6.  Kinetic analysis of target cell destruction by effector T cells. I. Delineation of parameters related to the frequency and lytic efficiency of killer cells.

Authors:  R M Thorn; C S Henney
Journal:  J Immunol       Date:  1976-12       Impact factor: 5.422

Review 7.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy.

Authors:  J E Edwards; R I Lehrer; E R Stiehm; T J Fischer; L S Young
Journal:  Ann Intern Med       Date:  1978-07       Impact factor: 25.391

8.  Effect of cyclophosphamide on experimental Nocardia asteroides infection in mice.

Authors:  B L Beaman; S Maslan
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Cyclophosphamide effects on murine cryptococcosis.

Authors:  J R Graybill; L Mitchell
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

10.  Macrophage-mediated natrual cytotoxicity against various target cells in vitro. I. Macrophages from diverse anatomical sites and different strains of rats and mice.

Authors:  R Keller
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

View more
  20 in total

1.  Expression of MHC class II antigens by conjunctival epithelial cells in trachoma: implications concerning the pathogenesis of blinding disease.

Authors:  D C Mabey; R L Bailey; D Dunn; D Jones; J H Williams; H C Whittle; M E Ward
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

2.  Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamma interferon, tumor necrosis factor, and interleukin-1.

Authors:  E Blasi; S Farinelli; L Varesio; F Bistoni
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

3.  Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice.

Authors:  E Cenci; L Romani; A Vecchiarelli; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

4.  Induction of natural killer cell activity by inactivated Candida albicans in mice.

Authors:  P Marconi; L Scaringi; L Tissi; M Boccanera; F Bistoni; E Bonmassar; A Cassone
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

5.  Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans.

Authors:  F Bistoni; A Vecchiarelli; R Mazzolla; P Puccetti; P Marconi; E Garaci
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

6.  A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.

Authors:  A Mencacci; A Torosantucci; R Spaccapelo; L Romani; F Bistoni; A Cassone
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Heterogeneous activity of immature and mature cells of the murine monocyte-macrophage lineage derived from different anatomical districts against yeast-phase Candida albicans.

Authors:  T Decker; M L Lohmann-Matthes; M Baccarini
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

Review 9.  An overview of macrophage-fungal interactions.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1986-02       Impact factor: 2.574

10.  Poly(I.C)-induced interferons enhance susceptibility of SCID mice to systemic candidiasis.

Authors:  J Jensen; A Vazquez-Torres; E Balish
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.